ACOTIAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H30N4O5S
Molecular Weight	450.552
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C

InChI

InChIKey=TWHZNAUBXFZMCA-UHFFFAOYSA-N

InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula	C21H30N4O5S
Molecular Weight	450.552
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23881665
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21123674 | https://www.ncbi.nlm.nih.gov/pubmed/10871292 | https://www.astellas.com/en/corporate/news/pdf/130605_1_Eg.pdf

Acotiamide (Acofide(®)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Acofide® is launched in Japan for treating functional dyspepsia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Acetylcholinesterase 207 Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21123674	Inhibitor 8297	3.0 µM [IC50]
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10871292	Antagonist 2778
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10871292	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Functional dyspepsia 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23881665	Primary		Approved 8429	ACOFIDE Approved Use Acofide (Acotiamide hydrochloride hydrate) improves gastrointestinal motility and promotes excretion of stomach contents by inhibiting acetylcholinesterase activities. It is usually used for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. Launch Date 1.36408321E12

PubMed

Title	Date	PubMed
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.	2008 Sep	18482254
Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.	2010 Jun	20553562
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.	2010 Jun	20059698

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 1 tablet (100mg of the active ingredient) at a time, 3 times a day before meals.

Route of Administration: Oral

In Vitro Use Guide

Acotiamide (0.3 and 1 uM) significantly enhanced the contraction of guinea pig gastric body strips induced by electrical field stimulation

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:26:26 UTC 2023` Edited by `admin` on `Fri Dec 15 16:26:26 UTC 2023`
Record UNII	D42OWK5383
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACOTIAMIDE

Official Name

English

acotiamide [INN]

Common Name

English

ACOTIAMIDE [MI]

Common Name

English

4-THIAZOLECARBOXAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)-

Systematic Name

English

Acotiamide [WHO-DD]

Common Name

English

N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)THIAZOLE-4-CARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C267